Menu
GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
    • Status of Assessments
    • Timeline of Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Contact Us
    • Call for Nomination
    • Topic Nomination
  • AUXILIARY MENU
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
    • Status of Assessments
    • Timeline of Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Contact Us
    • Call for Nomination
    • Topic Nomination

Publication

preliminary recommendation for the non-inclusion of eribulin in the treatment of soft tissue sarcoma in the PNF

[DEPARTMENT CIRCULAR NO. 2022- 2048] Creation of a Screening Committee for the Appointment of Health Technology Assessment Committee (HTAC) Members

[DEPARTMENT CIRCULAR NO. 2022- 0288] Nomination to the Health Technology Assessment Council (HTAC) Social Anthropologist Core Committee Member

[DEPARTMENT CIRCULAR NO. 2022- 0291] Health Technology Assessment Council (HTAC) Recommendation to include Potassium Citrate 15 mEq Extended Release (ER) Tablet in the Philippine National Formulary

[DEPARTMENT CIRCULAR NO. 2022- 0289] Health Technology Assessment Council (HTAC) Recommendation to include Tocilizumab in the Philippine National Formulary

[DEPARTMENT CIRCULAR NO. 2022- 0257] Changes to the Topic Nomination and Appeals Processes of the Philippine HTA Process Guide

[DEPARTMENT CIRCULAR NO. 2022- 0254] Updates on the HTAC processing of Minor Inclusion Application

[DEPARTMENT PERSONNEL ORDER NO. 2022- 2780 – A] Amendment to the Department Personnel Order No. 2021-2780 entitled “Creation of the pool of clinical experts for consultation on the evaluation of assessment topics” to include Expert Advisory Committee as additional experts

[DEPARTMENT PERSONNEL ORDER NO. 2022- 1245] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Drugs

preliminary recommendation for the inclusion of Potassium Citrate 1620 mg (15 mEq) tablet in the PNF.

Post navigation

← Older posts
656193
Users Today : 690
This Month : 20988
Total Users : 656193
Your IP Address : 44.192.47.87
Philippine Standard Time:
✕

Philippine Society of Microbiology and Infectious Diseases (PSMID) releases Philippine COVID-19 Living Recommendations

View the document on their website: https://www.psmid.org/philippine-covid-19-living-recommendations/